Brief Research Report
Published on 01 Feb 2023
Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study
in Multiple Sclerosis and Neuroimmunology
- 6,829 views
- 3 citations